Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that: Auro Vaccines, a wholly owned step-down subsidiary of the Company, has today, March 5, 2025, terminated the License Agreement (entered on September 27, 2023) with Hilleman Laboratories Singapore, to develop, manufacture and commercialize a pentavalent vaccine candidate used in children vaccination. The Auro Vaccines is not a material subsidiary to the Company and the termination of a Licence Agreement for a very early-stage vaccine asset is not a material event. It may also be noted that this termination of Agreement will not have any significant impact on the Company and/or its subsidiaries or its financials. In the event of any significant impact in future, the company will keep the exchanges informed about the same and provide necessary disclosures.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: